Navigation Links
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
Date:10/6/2008

Vice President and Chief Medical Officer at Ironwood.

"These novel findings provide valuable insight into the possible role of cGMP in alleviating intestinal pain and may explain the reduction in intestinal pain observed in patients with IBS-C treated with linaclotide in our Phase 2b studies," said Mark Currie, Ph.D., Senior Vice President, R&D and Chief Scientific Officer at Ironwood.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide reduced abdominal pain and relieved constipation-the hallmarks of the condition-throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week study period. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Healthcare costs associated with IBS exceed $25 billion ann
'/>"/>

SOURCE Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LONDON , July 29, 2014 ... 2014 Global Frost & Sullivan Best Practices Award ... solution is a cloud-based platform that connects digital ... - such as providers, pharmaceutical companies, prevention and ... electronics. Each year, Frost & ...
(Date:7/29/2014)... , July 29, 2014   Health 2.0 ... a keynote alongside visionary physicians Eric Topol , ... at the Health 2.0 8th Annual Fall Conference ... This year, Health 2.0 is set to host ... of the larger session on Consumer Tech & Wearables: ...
(Date:7/28/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... webcast to discuss financial results for the second quarter of ... 2014 at 4:30 p.m. ET. Conference call ... 2014 Time: 4:30 PM ET Listen via Internet: http://ir.pharmacyclics.com/events.cfm ... A webcast replay will be available on the Pharmacyclics website ...
Breaking Medicine Technology:Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2
... Inc. (OTC Bulletin Board: WGBS ), a leading developer ... an overview of the company at the 13th annual BIO CEO ... Hotel, Tuesday, February 15, 2011 at 11:30 a.m. Eastern time.  The ... may be accessed at www.wafergen.com . The BIO ...
... Caliper Life Sciences, Inc. (Nasdaq: CALP ) ... protocols on its Sciclone® NGS Workstation for Illumina,s TruSeq™ ... In addition to the automation protocols for TruSeq kits, ... library preparation kits, as well as for Agilent,s SureSelect™ ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2Caliper Life Sciences Announces Availability of Automated TruSeq™ Next Generation Sequencing Protocols 2
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma Clinical Trials ... only provided a comprehensive and thorough knowledge of the ... registration but also introduced the practical operation how to ... use the Chinese trial venues to keep drug development ... step. , The audiences of this guidebook are overseas ...
(Date:7/29/2014)... controversy over how best to treat patients after they,ve ... until the cancer comes back or provide men with ... a new study from Thomas Jefferson University ... patients make a more informed decision. , "We are ... author Robert Den, M.D., Assistant Professor of Radiation Oncology ...
(Date:7/29/2014)... principle suitable to find out which preferences patients have ... health economic evaluations, some (primarily methodological) issues still need ... pilot project by the German Institute for Quality and ... Process (AHP), CA is the second method tested by ... outcome-specific results to an overall value , In ...
(Date:7/29/2014)... repeatedly shown that death rates rise in association with ... in the summer of 2003, for example, resulted in ... by Dr. Alex-andra Schneider at the Institute of Epidemiology ... of extreme temperatures on the number of deaths caused ... both high and low temperatures in the study. , ...
(Date:7/29/2014)... stressful situations better than others, and it,s not ... differences in how they respond. , Researchers have ... of genetically identical mice that predicts how well ... , The findings, published July 29 in ... potential consequences of chronic stress -- such as ...
Breaking Medicine News(10 mins):Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Mortality rates increase due to extreme heat and cold 2Health News:A new brain-based marker of stress susceptibility 2
... 26 Concentric Medical, Inc., the global leader in ... announced that the company,s Merci Retrieval System(TM) has been ... August 2004. The Merci Retrieval System is a ... remove blood clots from patients suffering an ischemic stroke. ...
... Group at Frost & Sullivan is ... Presentation on the European Orphan Diseases Market to ... 2 p.m. GMT.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )Today,s pharmaceutical companies ... market because of the patent expiry of blockbuster ...
... of advanced health screening solutions in local communities, announces the deployment ... make the investment in the new unit in response to increased ... to increased capacity requirements related to the company,s planned geographical expansion ... ...
... Inc. anticipates growth and expansion of telemedicine services to include ... mental health centers. , ... N. ... continues to advance, regulations pertaining to hospital and physician reimbursement ...
... tumor characteristics that may help indicate which breast cancer patients ... to remove the unaffected breast. Published in the March ... of the American Cancer Society, the study could help patients ... diagnosed with breast cancer are known to be at increased ...
... procedure to remove the unaffected breast in breast cancer patients ... patients who have high-risk features as assessed by examining the ... to researchers at The University of Texas M. D. Anderson ... 1, 2009 issue of Cancer , may help physicians ...
Cached Medicine News:Health News:Concentric Medical Reaches Important Stroke Milestone 2Health News:Concentric Medical Reaches Important Stroke Milestone 3Health News:Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future? 2Health News:HealthYes! Announces Deployment of a New Mobile Health Screening Unit 2Health News:HealthYes! Announces Deployment of a New Mobile Health Screening Unit 3Health News:A Newly Approved CMS Medicare Package Expands Reimbursement Coverage for Telehealth Originating Sites Beginning January 1, 2009 2Health News:Study examines risk factors for cancer in unaffected breast of breast cancer patients 2Health News:Researchers identify risk factors for contralateral breast cancer 2
... eyewear and sunwear, inspired by ... personal style, with long lasting ... the collection include sophistication, elegance ... offer clean modern shapes, classic ...
... designs with children in mind, making eyewear ... stay-put cable temples. Its not surprising that ... as the best selling childrens collection from ... popular is its ability to keep pace ...
... The Calvin Klein Collection. Provocatively inspired ... - a bold outlook. Innovative structure: ... Modern technology enhances modern design. Technological ... and enhance the face., ,The Calvin ...
Inquire...
Medicine Products: